In today’s recent session, 1.39 million shares of the Rhythm Pharmaceuticals Inc (NASDAQ:RYTM) have been traded, and its beta is 2.37. Most recently the company’s share price was $81.41, and it changed around $16.27 or 24.98% from the last close, which brings the market valuation of the company to $5.18B. RYTM at last check was trading at a discount to its 52-week high of $69.89, offering almost 14.15% off that amount. The share price’s 52-week low was $40.61, which indicates that the recent value has risen by an impressive 50.12% since then. We note from Rhythm Pharmaceuticals Inc’s average daily trading volume that its 10-day average is 0.69 million shares, with the 3-month average coming to 667.39K.
Rhythm Pharmaceuticals Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.00. If we narrow it down even further, the data shows that 0 out of 12 analysts rate the stock as a Sell; another 4 rate it as Overweight. Among the rest, 0 recommended RYTM as a Hold, whereas 8 deemed it a Buy, and 0 rated it as Underweight. Rhythm Pharmaceuticals Inc is expected to report earnings per share of -0.62 for the current quarter.
Rhythm Pharmaceuticals Inc (NASDAQ:RYTM) trade information
Instantly RYTM has been showing a green trend so far today with a performance of 24.98% on intraday trading today. The performance over the last five days has remained in the green territory. The rise to weekly highs of 83.12 on recent trading dayincreased the stock’s daily price by 2.06%. The company’s shares are currently up 92.55% year-to-date, but still up 24.40% over the last five days. On the other hand, Rhythm Pharmaceuticals Inc (NASDAQ:RYTM) is 19.53% up in the 30-day period. We can see from the shorts that 4.76 million shares have been sold at a short interest cover period of 8.22 day(s).
The consensus price target as assigned by Wall Street analysts is $74, which translates to bulls needing to decrease their stock price by -10.01% from its current value. Analyst projections state that RYTM is forecast to be at a low of $70 and a high of $78.
Rhythm Pharmaceuticals Inc (RYTM) estimates and forecasts
The year-over-year growth rate is expected to be 34.86%, up from the previous year.
Consensus estimates provided by 11 financial analysts predict the company will bring in an average of 43.72M in revenue for the current quarter. 11 analysts expect Rhythm Pharmaceuticals Inc to make 46.92M in revenue for the current ending quarter. The company’s sales for the same quarters a year ago were 29.08M and 33.25M respectively. Analysts predict that the company’s current quarter sales will jump, forecast at 50.34%. Forecasts for the next quarter put sales growth at 41.12%.
Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -2.34%.
RYTM Dividends
Rhythm Pharmaceuticals Inc’s next quarterly earnings report is expected to be released on 2025-May-07.
Rhythm Pharmaceuticals Inc (NASDAQ:RYTM)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 0.67% of Rhythm Pharmaceuticals Inc shares, and 107.02% of them are in the hands of institutional investors. The stock currently has a share float of 107.74%. Rhythm Pharmaceuticals Inc stock is held by 324.0 institutions, with PRIMECAP MANAGEMENT CO/CA/ being the largest institutional investor. By 2024-06-30, it held 11.9852% of the shares, which is about 7.31 million shares worth $300.25 million.
BLACKROCK INC., with 11.0502% or 6.74 million shares worth $276.82 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
PRIMECAP Odyssey Funds-PRIMECAP Odyssey Aggressive Growth Fund and VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund were the top two Mutual Funds as of Apr 30, 2025 . The former held 3.79 shares worth $314.46 million, making up 5.95% of all outstanding shares. On the other hand, VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund held roughly 1.94 shares worth around $160.76 million, which represents about 3.04% of the total shares outstanding.
